Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zolucatetide
- Development stage
- Phase 2
- Lead developer
- Parabilis Medicines
- Modality
- Peptides
- Administration
- Intravenous
01
Overview
Zolucatetide (FOG-001) is a lead investigational alpha-helical peptide developed by Parabilis Medicines using its proprietary Helicon™ platform. It functions as a direct inhibitor of the β-catenin:TCF interaction, a crucial oncogenic driver implicated in various cancers. The drug is currently in clinical development, advancing toward a pivotal trial for desmoid tumors, an indication for which it has received FDA Fast Track Designation. It is also being evaluated for other tumor types, including colorectal cancer, adamantinomatous craniopharyngioma, ameloblastoma, and hepatocellular carcinoma, as well as a broader range of Wnt/β-catenin-driven tumors.
02
Targets
CTNNB1 (Beta-catenin)
Beyond the preview
Go deeper on zolucatetide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zolucatetide.